Dr. Oliver Sartor

Dr. Oliver Sartor, MD, is an internationally recognized medical oncologist specializing in prostate cancer and other genitourinary malignancies. He serves as Associate Dean for Oncology at Tulane University School of Medicine, Medical Director of the Tulane Cancer Center, and the C.E. and Bernadine Laborde Professor of Cancer Research. Dr. Sartor earned his medical degree from Tulane University School of Medicine, completed residency training in internal medicine at Tulane Medical Center, and pursued fellowship training in medical oncology at the National Cancer Institute. He is board-certified in Internal Medicine and Medical Oncology and is widely acknowledged as one of the world’s leading experts in advanced prostate cancer.

Dr. Sartor’s research focuses on the development of novel therapies for advanced prostate cancer, including radionuclide therapy, hormonal therapy, and immunotherapy. He has led pivotal trials of agents such as radium-223 and lutetium-177–PSMA therapy, which have transformed treatment standards for metastatic castration-resistant prostate cancer. His work has been published in leading journals and has directly influenced international guidelines. A leader in translational and clinical research, Dr. Sartor has authored hundreds of peer-reviewed articles and remains at the forefront of therapeutic innovation in prostate cancer.

In addition to his clinical and research leadership, Dr. Sartor is a committed educator and mentor. He has trained numerous fellows and junior faculty, many of whom have assumed leadership roles in academic oncology. He is an active member of professional societies, serves on editorial boards, and participates in advisory groups shaping the future of prostate cancer therapy. Through his dedication to patient care, clinical investigation, and mentorship, Dr. Oliver Sartor continues to advance the global field of genitourinary oncology.